start-ver=1.4 cd-journal=joma no-vol= cd-vols= no-issue= article-no= start-page= end-page= dt-received= dt-revised= dt-accepted= dt-pub-year=2021 dt-pub=20210920 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset en-subtitle= kn-subtitle= en-abstract= kn-abstract=This prespecified subanalysis of the global, randomized controlled phase Ill KEYNOTE-024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non-small-cell lung cancer without EGFR/ALK alterations and a programmed death-ligand 1 (PD-L1) tumor proportion score of 50% or greater evaluated clinical outcomes among patients enrolled in Japan. Treatment consisted of pembrolizumab 200 mg every 3 weeks (35 cycles) or platinum-based chemotherapy (four to six cycles). The primary end-point was progression-free survival; secondary end-points included overall survival and safety. Of 305 patients randomized in KEYNOTE-024 overall, 40 patients were enrolled in Japan (all received treatment: pembrolizumab, n = 21; chemotherapy, n = 19). The hazard ratio (HR) for progression-free survival by independent central review (data cut-off date, 10 July 2017) was 0.25 (95% confidence interval [CI], 0.10-0.64; one-sided, nominal P = .001). The HR for overall survival (data cut-off date, 15 February 2019) was 0.39 (95% CI, 0.17-0.91; one-sided, nominal P = .012). Treatment-related adverse events occurred in 21/21 (100%) pembrolizumab-treated and 18/19 (95%) chemotherapy-treated patients; eight patients (38%) and nine patients (47%), respectively, had grade 3-5 events. Immune-mediated adverse events and infusion reactions occurred in 11 patients (52%) and four patients (21%), respectively; four patients (19%) and one patient (5%), respectively, had grade 3-5 events. Consistent with results from KEYNOTE-024 overall, first-line pembrolizumab improved progression-free survival and overall survival vs chemotherapy with manageable safety among Japanese patients with metastatic non-small-cell lung cancer without EGFRIALK alterations and a PD-L1 tumor proportion score of 50% or greater. en-copyright= kn-copyright= en-aut-name=SatouchiMiyako en-aut-sei=Satouchi en-aut-mei=Miyako kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=NosakiKaname en-aut-sei=Nosaki en-aut-mei=Kaname kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=TakahashiToshiaki en-aut-sei=Takahashi en-aut-mei=Toshiaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=NakagawaKazuhiko en-aut-sei=Nakagawa en-aut-mei=Kazuhiko kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=AoeKeisuke en-aut-sei=Aoe en-aut-mei=Keisuke kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=KurataTakayasu en-aut-sei=Kurata en-aut-mei=Takayasu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=SekineAkimasa en-aut-sei=Sekine en-aut-mei=Akimasa kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= en-aut-name=HoriikeAtsushi en-aut-sei=Horiike en-aut-mei=Atsushi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=8 ORCID= en-aut-name=FukuharaTatsuro en-aut-sei=Fukuhara en-aut-mei=Tatsuro kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=9 ORCID= en-aut-name=SugawaraShunichi en-aut-sei=Sugawara en-aut-mei=Shunichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=10 ORCID= en-aut-name=UmemuraShigeki en-aut-sei=Umemura en-aut-mei=Shigeki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=11 ORCID= en-aut-name=SakaHideo en-aut-sei=Saka en-aut-mei=Hideo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=12 ORCID= en-aut-name=OkamotoIsamu en-aut-sei=Okamoto en-aut-mei=Isamu kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=13 ORCID= en-aut-name=YamamotoNobuyuki en-aut-sei=Yamamoto en-aut-mei=Nobuyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=14 ORCID= en-aut-name=SakaiHiroshi en-aut-sei=Sakai en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=15 ORCID= en-aut-name=KishiKazuma en-aut-sei=Kishi en-aut-mei=Kazuma kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=16 ORCID= en-aut-name=KatakamiNobuyuki en-aut-sei=Katakami en-aut-mei=Nobuyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=17 ORCID= en-aut-name=HorinouchiHidehito en-aut-sei=Horinouchi en-aut-mei=Hidehito kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=18 ORCID= en-aut-name=HidaToyoaki en-aut-sei=Hida en-aut-mei=Toyoaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=19 ORCID= en-aut-name=OkamotoHiroaki en-aut-sei=Okamoto en-aut-mei=Hiroaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=20 ORCID= en-aut-name=AtagiShinji en-aut-sei=Atagi en-aut-mei=Shinji kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=21 ORCID= en-aut-name=OhiraTatsuo en-aut-sei=Ohira en-aut-mei=Tatsuo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=22 ORCID= en-aut-name=HanShi Rong en-aut-sei=Han en-aut-mei=Shi Rong kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=23 ORCID= en-aut-name=NoguchiKazuo en-aut-sei=Noguchi en-aut-mei=Kazuo kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=24 ORCID= en-aut-name=EbianaVictoria en-aut-sei=Ebiana en-aut-mei=Victoria kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=25 ORCID= en-aut-name=HottaKatsuyuki en-aut-sei=Hotta en-aut-mei=Katsuyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=26 ORCID= affil-num=1 en-affil=Department of Thoracic Oncology, Hyogo Cancer Center kn-affil= affil-num=2 en-affil=Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center kn-affil= affil-num=3 en-affil=Division of Thoracic Oncology, Shizuoka Cancer Center kn-affil= affil-num=4 en-affil=Department of Medical Oncology, Faculty of Medicine, Kindai University kn-affil= affil-num=5 en-affil=Department of Medical Oncology, National Hospital Organization Yamaguchi Ube Medical Center kn-affil= affil-num=6 en-affil=Department of Thoracic Oncology, Kansai Medical University Hospital kn-affil= affil-num=7 en-affil=Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center kn-affil= affil-num=8 en-affil=Department of Thoracic Medical Oncology, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research kn-affil= affil-num=9 en-affil=Miyagi Cancer Center kn-affil= affil-num=10 en-affil=Department of Pulmonary Medicine, Sendai Kousei Hospital kn-affil= affil-num=11 en-affil=Department of Thoracic Oncology, National Cancer Center Hospital East kn-affil= affil-num=12 en-affil=Department of Respiratory Medicine and Medical Oncology, National Hospital Organization Nagoya Medical Center kn-affil= affil-num=13 en-affil=Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University kn-affil= affil-num=14 en-affil=Internal Medicine III, Wakayama Medical University kn-affil= affil-num=15 en-affil=Department of Thoracic Oncology, Saitama Cancer Center kn-affil= affil-num=16 en-affil=Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital kn-affil= affil-num=17 en-affil=Division of Integrated Oncology, Institute of Biomedical Research and Innovation Hospital kn-affil= affil-num=18 en-affil=Department of Thoracic Oncology, National Cancer Center Hospital kn-affil= affil-num=19 en-affil=Department of Thoracic Oncology, Aichi Cancer Center kn-affil= affil-num=20 en-affil=Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen’s Hospital kn-affil= affil-num=21 en-affil=Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center kn-affil= affil-num=22 en-affil=Department of Surgery, Tokyo Medical University kn-affil= affil-num=23 en-affil=MSD K.K. kn-affil= affil-num=24 en-affil=MSD K.K. kn-affil= affil-num=25 en-affil=Merck & Co., Inc. kn-affil= affil-num=26 en-affil=Center for Innovative Clinical Medicine, Okayama University Hospital kn-affil= en-keyword=Japan kn-keyword=Japan en-keyword=non-small-cell lung carcinoma kn-keyword=non-small-cell lung carcinoma en-keyword=PD-L1 protein kn-keyword=PD-L1 protein en-keyword=pembrolizumab kn-keyword=pembrolizumab en-keyword=treatment outcome kn-keyword=treatment outcome END start-ver=1.4 cd-journal=joma no-vol=36 cd-vols= no-issue=2 article-no= start-page=61 end-page=66 dt-received= dt-revised= dt-accepted= dt-pub-year=2002 dt-pub=200203 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=Cytotoxicity of the Bacillus thuringiensis Crystal Protein against Mammalian Cells en-subtitle= kn-subtitle= en-abstract= kn-abstract=The crystal proteins produced by Bacillus thuringiensis subsp, israelensis (Bti) and subsp. coreanensis A1519 strain were examined for the cytotoxicity against MOLT-4 and HeLa cells by MTT assay and LDH assay, The A1519 crystal proteins processed by proteinase K exhibited the specific cell-killing activity toward MOLT-4 with little damage to the cell membrane, On the other hand, the Bti crystal proteins processed by proteinase K caused the substantial damage to the cell membrane of both MOLT-4 and HeLa, leading to the cell lysis. The non-digested crystal proteins of both strains exhibited no cytotoxicity, These data suggested that while the Bti crystal proteins caused the colloid-osmotic swelling and cell lysis of MOLT-4 and HeLa, the proteinase K-digested A1519 crystal proteins induced the specific cell death of MOLT-4 through a mechanism other than that of Bti. en-copyright= kn-copyright= en-aut-name=YamagiwaMasashi en-aut-sei=Yamagiwa en-aut-mei=Masashi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=NambaAkitoshi en-aut-sei=Namba en-aut-mei=Akitoshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=AkaoTetsuyuki en-aut-sei=Akao en-aut-mei=Tetsuyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=MizukiEiichi en-aut-sei=Mizuki en-aut-mei=Eiichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=OhbaMichio en-aut-sei=Ohba en-aut-mei=Michio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=SakaiHiroshi en-aut-sei=Sakai en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= affil-num=1 en-affil= kn-affil=Department of Bioscience and Biotechnology, Okayama University affil-num=2 en-affil= kn-affil=Department of Bioscience and Biotechnology, Okayama University affil-num=3 en-affil= kn-affil=Biotechnology and Food Research Institute, Fukuoka Industrial Technology Center affil-num=4 en-affil= kn-affil=Biotechnology and Food Research Institute, Fukuoka Industrial Technology Center affil-num=5 en-affil= kn-affil=Graduate School of Agriculture, Kyusyu University affil-num=6 en-affil= kn-affil=Department of Bioscience and Biotechnology, Okayama University END start-ver=1.4 cd-journal=joma no-vol=37 cd-vols= no-issue=2 article-no= start-page=67 end-page=72 dt-received= dt-revised= dt-accepted= dt-pub-year=2003 dt-pub=200303 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=The role of helices of domain I for the insecticidal activity of Bacillus thuringiensis Cry4A toxin en-subtitle= kn-subtitle= en-abstract= kn-abstract=An active form of Cry4A is a heterodimer of the 20- and 45-kDa fragments that are derived from the 130-kDa Cry4A protoxin. To investigate the function of these two fragments, several deletion mutants were constructed and expressed in E.coli as the GST (glutathione-S-transferase) fusion proteins. The results of the bioassay against Culex pipiens larvae showed that the interaction of two fragments of Cry4A was necessary for the toxicity, and that the C-terminal 67 amino acids of the 20-kDa fragment corresponding to the helices α4 and α5 were involved in determining the insecticidal activity. Surprisingly the lack of helix α5 did not affect the toxicity to C. pipiens, suggesting that the role of helix α5 of Cry4A was different from that postulated in the case of Cry4A toxins. en-copyright= kn-copyright= en-aut-name=YamagiwaMasashi en-aut-sei=Yamagiwa en-aut-mei=Masashi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=SakaiHiroshi en-aut-sei=Sakai en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= affil-num=1 en-affil= kn-affil=Department of Bioscience and Biotechnology Okayama University affil-num=2 en-affil= kn-affil=Department of Bioscience and Biotechnology Okayama University END start-ver=1.4 cd-journal=joma no-vol=38 cd-vols= no-issue=1-2 article-no= start-page=97 end-page=100 dt-received= dt-revised= dt-accepted= dt-pub-year=2004 dt-pub=200403 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=The cytotoxicity of Bacillus thuringiensis subsp. coreanensis A2316 strain against the human leukemic T cell en-subtitle= kn-subtitle= en-abstract= kn-abstract=Bacillus thuringiensis subsp. coreanensis A2316 is a newly isolated strain from Yonakunijima Island in Japan. It produces the proteinaceous inclusion body (crystal) which has no insecticidal and hemolytic activities. When the crystal proteins were digested by proteinase K, they exhibited the strong cytotoxicity against human leukemic T cell, MOLT-4. The proteinase K-digested A2316 crystal proteins have little damage upon the cell membrane of MOLT-4, suggesting that the cell death of MOLT-4 was induced through a mechanism other than the colloid-osmotic swelling and cell lysis as caused by hitherto known B. thuringiensis crystal proteins. The 29-kDa polypeptide proved to be an active component of the proteinase K-digested A2316 crystal proteins. EC(50) of the purified 29-kDa polypeptide was 0.0579 μg/ml. The N-terminal amino acid sequence of the 29-kDa polypeptide was identical with that of p29 produced by B. thuringiensis A1519 strain and shared no significant homology with all the known proteins, suggesting that this polypeptide belong to a new family of B. thuringiensis crystal proteins. en-copyright= kn-copyright= en-aut-name=YamagiwaMasashi en-aut-sei=Yamagiwa en-aut-mei=Masashi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=1 ORCID= en-aut-name=HiraoTaichi en-aut-sei=Hirao en-aut-mei=Taichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=2 ORCID= en-aut-name=KiyomiMasaaki en-aut-sei=Kiyomi en-aut-mei=Masaaki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=3 ORCID= en-aut-name=AkaoTetsuyuki en-aut-sei=Akao en-aut-mei=Tetsuyuki kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=4 ORCID= en-aut-name=MizukiEiichi en-aut-sei=Mizuki en-aut-mei=Eiichi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=5 ORCID= en-aut-name=OhbaMichio en-aut-sei=Ohba en-aut-mei=Michio kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=6 ORCID= en-aut-name=SakaiHiroshi en-aut-sei=Sakai en-aut-mei=Hiroshi kn-aut-name= kn-aut-sei= kn-aut-mei= aut-affil-num=7 ORCID= affil-num=1 en-affil= kn-affil=Department of Bioscience and Biotechnology Okayama University affil-num=2 en-affil= kn-affil=Department of Bioscience and Biotechnology Okayama University affil-num=3 en-affil= kn-affil=Department of Bioscience and Biotechnology, Faculty of Engineering, Okayama University affil-num=4 en-affil= kn-affil=Biotechnology and Food Research Institute Fukuoka Industrial Technology Center affil-num=5 en-affil= kn-affil=Biotechnology and Food Research Institute Fukuoka Industrial Technology Center affil-num=6 en-affil= kn-affil=Graduate School of Agriculture Kyushu University affil-num=7 en-affil= kn-affil=Department of Bioscience and Biotechnology Okayama University END start-ver=1.4 cd-journal=joma no-vol=25 cd-vols= no-issue= article-no= start-page=2 end-page=6 dt-received= dt-revised= dt-accepted= dt-pub-year=2003 dt-pub=200308 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=微生物農薬による害虫の防除と環境保全 en-subtitle= kn-subtitle= en-abstract= kn-abstract= en-copyright= kn-copyright= en-aut-name=SakaiHiroshi en-aut-sei=Sakai en-aut-mei=Hiroshi kn-aut-name=酒井裕 kn-aut-sei=酒井 kn-aut-mei=裕 aut-affil-num=1 ORCID= en-aut-name=YamagiwaMasashi en-aut-sei=Yamagiwa en-aut-mei=Masashi kn-aut-name=山際雅詩 kn-aut-sei=山際 kn-aut-mei=雅詩 aut-affil-num=2 ORCID= affil-num=1 en-affil= kn-affil=岡山大学工学部生物機能工学科 affil-num=2 en-affil= kn-affil=岡山大学工学部生物機能工学科 END start-ver=1.4 cd-journal=joma no-vol=93 cd-vols= no-issue=5-6 article-no= start-page=579 end-page=592 dt-received= dt-revised= dt-accepted= dt-pub-year=1981 dt-pub=19810630 dt-online= en-article= kn-article= en-subject= kn-subject= en-title=Body surface isopotential maps in the case of R.B.B.B. special reference to Atrial Septal Defect. (Comparative study of the data from cardiac catetherization and two dimensional echocardiograms.) kn-title=右脚ブロックの体表面心臓電位図（特に心房中隔欠損症を中心として）―超音波検査,右心カテーテル検査との対比― en-subtitle= kn-subtitle= en-abstract= kn-abstract=A body surface isopotential map was recorded in 30 cases of ASD and 3 cases of ECD with right bundle branch block in ECG, then analyzed in comparison with results obtained by cardiac catetherization and two dimensional echocardiograms. 1) In all cases of right bundle branch block, breakthrough minimum appeared later and shifted to the left compared with the normal. 2) Breakthrough minimum of ASD and ECD appeared progressively later associated with Qp/Qs ratio and left to right intracardiac shunt ratio obtained with cardiac catetherization and RVDd with echocardiogram. Breakthrough minimum of ASD and ECD moved to the left accompanied by increases in mean RV pressure, mean PA pressure and RVDd. 3) R'max voltage, the maximum positive potential in the late stage of ventricular depolarization on the right precordial area, increased and correlated well with the mean RV pressure and left to right shunt ratio increment. 4) In the case of ASD, breakthrough minimum appeared later and shifted to the left along with age. en-copyright= kn-copyright= en-aut-name=YoshidaHidenori en-aut-sei=Yoshida en-aut-mei=Hidenori kn-aut-name=吉田英紀 kn-aut-sei=吉田 kn-aut-mei=英紀 aut-affil-num=1 ORCID= en-aut-name=IhoriyaKazuo en-aut-sei=Ihoriya en-aut-mei=Kazuo kn-aut-name=庵谷和夫 kn-aut-sei=庵谷 kn-aut-mei=和夫 aut-affil-num=2 ORCID= en-aut-name=NagahanaHaruki en-aut-sei=Nagahana en-aut-mei=Haruki kn-aut-name=長花晴樹 kn-aut-sei=長花 kn-aut-mei=晴樹 aut-affil-num=3 ORCID= en-aut-name=NishiharaMasanobu en-aut-sei=Nishihara en-aut-mei=Masanobu kn-aut-name=西原正信 kn-aut-sei=西原 kn-aut-mei=正信 aut-affil-num=4 ORCID= en-aut-name=HyodoTatsuo en-aut-sei=Hyodo en-aut-mei=Tatsuo kn-aut-name=兵頭多津男 kn-aut-sei=兵頭 kn-aut-mei=多津男 aut-affil-num=5 ORCID= en-aut-name=UchidaToshiaki en-aut-sei=Uchida en-aut-mei=Toshiaki kn-aut-name=内田俊明 kn-aut-sei=内田 kn-aut-mei=俊明 aut-affil-num=6 ORCID= en-aut-name=KimuraMasashi en-aut-sei=Kimura en-aut-mei=Masashi kn-aut-name=木村正司 kn-aut-sei=木村 kn-aut-mei=正司 aut-affil-num=7 ORCID= en-aut-name=TakedaKou en-aut-sei=Takeda en-aut-mei=Kou kn-aut-name=武田光 kn-aut-sei=武田 kn-aut-mei=光 aut-affil-num=8 ORCID= en-aut-name=FujiiAkinobu en-aut-sei=Fujii en-aut-mei=Akinobu kn-aut-name=藤井章伸 kn-aut-sei=藤井 kn-aut-mei=章伸 aut-affil-num=9 ORCID= en-aut-name=SaitoDaiji en-aut-sei=Saito en-aut-mei=Daiji kn-aut-name=斉藤大治 kn-aut-sei=斉藤 kn-aut-mei=大治 aut-affil-num=10 ORCID= en-aut-name=TanataniSetsuro en-aut-sei=Tanatani en-aut-mei=Setsuro kn-aut-name=種谷節郎 kn-aut-sei=種谷 kn-aut-mei=節郎 aut-affil-num=11 ORCID= en-aut-name=KitaToshimasa en-aut-sei=Kita en-aut-mei=Toshimasa kn-aut-name=喜多利正 kn-aut-sei=喜多 kn-aut-mei=利正 aut-affil-num=12 ORCID= en-aut-name=SakaiHiroshi en-aut-sei=Sakai en-aut-mei=Hiroshi kn-aut-name=堺裕 kn-aut-sei=堺 kn-aut-mei=裕 aut-affil-num=13 ORCID= en-aut-name=HaraokaShoichi en-aut-sei=Haraoka en-aut-mei=Shoichi kn-aut-name=原岡昭一 kn-aut-sei=原岡 kn-aut-mei=昭一 aut-affil-num=14 ORCID= affil-num=1 en-affil= kn-affil=岡山大学医学部第一内科教室 affil-num=2 en-affil= kn-affil=岡山大学医学部第一内科教室 affil-num=3 en-affil= kn-affil=岡山大学医学部第一内科教室 affil-num=4 en-affil= kn-affil=岡山大学医学部第一内科教室 affil-num=5 en-affil= kn-affil=岡山大学医学部第一内科教室 affil-num=6 en-affil= kn-affil=岡山大学医学部第一内科教室 affil-num=7 en-affil= kn-affil=岡山大学医学部第一内科教室 affil-num=8 en-affil= kn-affil=岡山大学医学部第一内科教室 affil-num=9 en-affil= kn-affil=岡山大学医学部第一内科教室 affil-num=10 en-affil= kn-affil=岡山大学医学部第一内科教室 affil-num=11 en-affil= kn-affil=榊原十全病院 affil-num=12 en-affil= kn-affil=榊原十全病院 affil-num=13 en-affil= kn-affil=榊原十全病院 affil-num=14 en-affil= kn-affil=岡山大学医学部附属病院中央検査部 en-keyword=体表面心臓電位図 kn-keyword=体表面心臓電位図 en-keyword=右脚ブロック kn-keyword=右脚ブロック en-keyword=心房中隔欠損 kn-keyword=心房中隔欠損 en-keyword=Breakthrough kn-keyword=Breakthrough END start-ver=1.4 cd-journal=joma no-vol=35 cd-vols= no-issue=1-2 article-no= start-page=147 end-page=154 dt-received= dt-revised= dt-accepted= dt-pub-year=2001 dt-pub=20010327 dt-online= en-article= kn-article= en-subject= kn-subject= en-title= kn-title=The role of interhelical cleavage for insecticidal activityof Bacillus thuringiensis Cry4A toxin en-subtitle= kn-subtitle= en-abstract= kn-abstract=The Cry4A toxin is a dipteran-specific insecticidal protein produced by Bacillus thuringiensis subsp. israelensis as a protoxin of 130 kDa. Its active form is a heterodimer of 20- and 45-kDa fragments which is generated by an interhelical cleavage of a 60-kDa intermediate at the position of Gln236 between α5 and α6 helices in domain I. On the other hand, Cry1Aa, which is also produced as a 130-kDa protoxin but toxic to lepidopteran larvae, was processed into the active 60-kDa fragment with no additional cleavage. To investigate the role of the intramolecular cleavage of Cry4A for its insecticidal activity, the loop between α5 and α6 of Cry4A which includes the cleavage site was substituted for the corresponding region of Cry1Aa. The resulting mutant designated GST-60Loop was expressed as a GST-fusion protein. A difference of the processing profile was observed between GST-60 and GST-60Loop in the in vitro digestion assay by trypsin, and the insecticidal activity of GST-60Loop was two-fold lower than that of GST-60. These results suggested that the interhelical cleavage of Cry4A promoted the toxicity against C. pipiens larvae. en-copyright= kn-copyright= en-aut-name=YamagiwaMasashi en-aut-sei=Yamagiwa en-aut-mei=Masashi kn-aut-name=山際雅詩 kn-aut-sei=山際 kn-aut-mei=雅詩 aut-affil-num=1 ORCID= en-aut-name=SakaiHiroshi en-aut-sei=Sakai en-aut-mei=Hiroshi kn-aut-name=酒井裕 kn-aut-sei=酒井 kn-aut-mei=裕 aut-affil-num=2 ORCID= affil-num=1 en-affil= kn-affil=Department of Bioscience and Biotechnology affil-num=2 en-affil= kn-affil=Department of Bioscience and Biotechnology END